Know Cancer

or
forgot password

A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer


Phase 3
20 Years
74 Years
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer


Inclusion Criteria:



All patients had histologically or cytologically confirmed locally advanced NSCLC. All
patients must not have undergone any previous therapy for NSCLC. Patients had to have
measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or
1, and to be less than 75 years old. Adequate organ (bone marrow, renal, liver, heart,
and lung) function was required. All patients gave written informed consent.

Exclusion Criteria:

The exclusion criteria consisted of pulmonary fibrosis, pleural effusion, pregnancy,
lactation, active concurrent malignancies, severe drug allergies, myocardial infarction,
severe heart disease, uncontrollable diabetes mellitus, and infection. -

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Survival

Principal Investigator

Hisao Uejima, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

West Japan Thoracic Oncology Group

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

WJTOG0105

NCT ID:

NCT00144053

Start Date:

April 2001

Completion Date:

Related Keywords:

  • Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location